-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Foralumab in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Foralumab in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Foralumab in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:...
-
Product Insights
Secondary Progressive Multiple Sclerosis (SPMS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Secondary Progressive Multiple Sclerosis (SPMS) - Drugs In Development, 2023’, provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Thymic Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Thymic Carcinoma - Drugs In Development, 2023’, provides an overview of the Thymic Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thymic Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Thymoma (Thymic Epithelial Tumor) – Drugs In Development, 2023
Global Markets Direct’s, ‘Thymoma (Thymic Epithelial Tumor) - Drugs In Development, 2023’, provides an overview of the Thymoma (Thymic Epithelial Tumor) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thymoma (Thymic Epithelial Tumor), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Intracerebral Hemorrhage – Drugs In Development, 2023
Global Markets Direct’s, ‘Intracerebral Hemorrhage - Drugs In Development, 2023’, provides an overview of the Intracerebral Hemorrhage pipeline landscape. The report provides comprehensive information on the therapeutics under development for Intracerebral Hemorrhage, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-1821736 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-1821736 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-1821736 in Solid Tumor Drug Details: BI-1821736 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARTS-021 in Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARTS-021 in Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ARTS-021 in Lung Cancer Drug Details: ARTS-021 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Foralumab in Secondary Progressive Multiple Sclerosis (SPMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Foralumab in Secondary Progressive Multiple Sclerosis (SPMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Foralumab in Secondary Progressive Multiple Sclerosis (SPMS) Drug...